|Japanese | English|
|Keyword：||Development of therapies against neuromuscular diseases, diabetes and cancer.
Signal transduction of activin, myostatin and other cytokines.
Drug delivery system.
|E-Mail address：||tsuchida@@fujita-hu.ac.jp delete one @|
|Research Information (#1)|
|Research section-1：||Developmnt of therapy against muscular dystrophy and related neuromuscular diseases|
|Research Information (#2)|
|Research section-2：||Obesity, diabetes, differentiation of adipocytes|
|Research Information (#4)|
|Research section-4：||nanomedicine, DDS|
|Organization / Department (#1)|
|Organization-1：||Fujita Health University|
|Department(1) 1：||Institute for Comprehensive Medical Science|
|Department(2) 1：||Division for Therapies against Intractable Diseases|
|Address-1：||1-98,Toyoake aichi JAPAN|
|Academic Meeting / Research Meeting (#1)|
|Academic Meeting-1：||The Molecular Biology Society of Japan|
|Academic Meeting / Research Meeting (#2)|
|Academic Meeting-2：||The Japanese Biochemical Society|
|Academic Meeting / Research Meeting (#3)|
|Academic Meeting-3：||The Japan Endocrine Society|
|Academic Meeting / Research Meeting (#4)|
|Academic Meeting-4：||The Japan Neuroscience Society|
|Academic Meeting / Research Meeting (#5)|
|Academic Meeting-5：||The Japanese Society for Regenerative Medicine|
|Academic Meeting / Research Meeting (#6)|
|Academic Meeting-6：||The Endocrine Society|
|Academic Meeting / Research Meeting (#7)|
|Academic Meeting-7：||World Muscle Society|
|Research History  (#2)|
|Papers-2：||K. Tsuchida, J.M. Vaughan, E. Wiater, D. Gaddy-Kurten, W.W. Vale. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology 136, 5493-5503 (1995)
D. Gaddy-Kurten, K. Tsuchida, W. Vale. Activins and the receptor serine kinase superfamily. Recent Prog. Horm. Res. 50, 109-129 (1995)
|Books-2：||K. Tsuchida, M. Hashimoto, K. Pickham, D. Gaddy-Kurten, A. Corrigan, K. Lewis, J. Vaughan, L. Bilezikjian, W. Vale
Activins and the receptor serine kinase superfamily
Frontiers in Endocrinology, New Achievements in Research of Ovarian Function
P. 49-56 (1995) Ares-Serono Symposia Publications
|Research History  (#3)|
|Papers-3：||K. Tsuchida, P.E. Sawchenko, S.-I. Nishikawa, W.W. Vale. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF-β superfamily from rat brain. Mol. Cell. Neurosci. 7(6), 467-478 (1996)
|Books-3：||K.M. Pickham, K. Tsuchida, W. Vale
Activin and the receptor serine kinase family
Molecular Mechanisms of Neuronal Communication
P. 129-147 (1996) Elsevier Science Ltd.
|Research History  (#4)|
|Papers-4：||H. Kataoka, N. Takakura, S. Nishikawa, K. Tsuchida, H. Kodama, T. Kunisada, W. Risau, T. Kita, S.-I. Nishikawa. Expressions of PDGF receptor alpha, c-kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev. Growth Differ. 39, 729-740 (1997)
M. Kanatsu, N. Takakura, H. Kataoka, K. Tsuchida, S. Nishikawa, S.-I. Nishikawa.
In vitro analysis of potency restriction during epiblast differentiation. Leukemia Suppl 3, 457-459 (1997)
|Books-4：||K. Tsuchida, W.W. Vale, N. Suzuki, E. Nishimura, M. Shinohara, H. Kataoka, S. Nishikawa, S.-I. Nishikawa
Activin Signal Transduction and the Role of TGF-b Superfamily in Cell Differentiation
Inhibin, Activin and Follistatin P. 254-263 (1997) Springer-Verlag
|Research History  (#5)|
|Papers-5：||H. Yoshida, N. Takakura, M. Hirashima, H. Kataoka, K. Tsuchida, S. Nishikawa,S. Nishikawa. Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Dev. Comp. Immunol. 22(3), 321-332 (1998)|
|Research History  (#7)|
|Papers-7：||H.Shoji, K.Tsuchida, H.Kishi, N.Yamakawa, T.Matsuzaki, Z.Liu , T.Nakamura, H.Sugino. Identification of a PDZ protein that associates with activin type II receptors. J. Biol. Chem. 275, 5485-5492 (2000)
K. Sumitomo, A. Kurisaki, N. Yamakawa, K. Tsuchida, E. Shimizu, S. Sone, H. Sugino. Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines. Cancer Lett. 155, 37-46 (2000)
K. Tsuchida, K.Y. Arai, Y. Kuramoto, N. Yamakawa, Y. Hasegawa, H. Sugino.
Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-β family. J. Biol. Chem. 275, 40788-40796 (2000)
O. Hashimoto, N. Kawasaki, K. Tsuchida, S. Shimasaki, T. Hayakawa, H. Sugino. Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin. Cell Signal. 12, 565-571 (2000)
|Books-7：||H. Sugino, K. Tsuchida
Activin and Follistatin, Skeletal Growth Factors (E. Canalis Ed.)
P. 251-263 (2000) Lippincott Williams &Wilkins
Intracellular and extracellular control of activin function by novel regulatory molecules.
Serono International Workshop. Melbourne, Australia (2000)
|Research History  (#8)|
|Papers-8：||K. Tsuchida, T. Matsuzaki, N. Yamakawa, Z.H. Liu, H. Sugino.
Intracellular and extracellular control of activin function by novel regulatory molecules. Mol. Cell. Endo. 180, 25-31 (2001)
T. Tolkacheva, M. Boddapati, A. Sanfiz, K. Tsuchida, A.C. Kimmelman, A.M.L. Chan. Regulation of PTEN binding to the PDZ2 domain of ARIP1/MAGI2 by two putative phosphorylation sites at Threonine codon 382 & 383.
Cancer Research 61, 4985-4989 (2001)
|Research History  (#9)|
|Papers-9：||M. Nakatani, N. Yamakawa, T. Matsuzaki, S. Shimasaki, H. Sugino, K. Tsuchida. Genomic organization and promoter analysis of mouse follistatin-related gene (FLRG). Mol. Cell. Endo. 189, 117-123 (2002)
T. Matsuzaki, S. Hanai, H. Kishi, Z.H. Liu, Y.L. Bao, A. Kikuchi, K. Tsuchida, H. Sugino. Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway.
J. Biol. Chem. 277, 19008-19018 (2002)
N. Yamakawa, K. Tsuchida, H. Sugino.
The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors. EMBO Journal 21, 1684-1694 (2002)
O. Hashimoto, K. Tsuchida, Y. Ushiro, Y. Hosoi, N. Hoshi, H. Sugino, Y. Hasegawa.
cDNA cloning and expression of human activin betaE subunit.
Mol. Cell. Endo. 194, 117-122 (2002)
|Research History  (#10)|
|Papers-10：||K.Y. Arai, K. Tsuchida, K. Uehara, K. Taya, H. Sugino.
Characterization of rat follistatin-related gene (FLRG): effects of estrous cycle stage and pregnancy on its mRNA expression in rat reproductive tissues.
Biology of Reproduction 68, 199-206 (2003)
M. Yokozeki, E. Afanador, M. Nishi, K. Kaneko, C. Deng, K. Yokode, K. Tsuchida, H. Sugino, K. Moriyama.Smad3 is required for enamel biomineralization.
Biochem. Biophys. Res. Comm. 305, 684-690 (2003)
H.Q.Wang, K. Takebayashi, K. Tsuchida, M. Nishimura, Y. Noda.
Follistatin-related gene (FLRG) expression in human endometrium: sex steroid hormones regulate the expression of FLRG in cultured human endometrial stromal cells.
J. Clin. Endo. & Metab. 88, 4432-4439 (2003)
M. Funaba, T.Ikeda, M.Murakami, K. Ogawa, K.Tsuchida, H. Sugino, M. Abe.
Transcriptional activation of mouse mast cell protease-7 by activin and transforming growth factor-beta is inhibited by microphthalmia- associated transcription factor.
J. Biol. Chem. 278(52), 52032-52041 (2003)
基本編 第４章 BMP/TGF-beta/アクチビン受容体シグナル系、羊土社
P. 45-53 (2003)
|Research History  (#11)|
|Papers-11：||H. Miyamoto, T. Murakami, K. Tsuchida, H. Sugino, S. Tashiro. Tumor-stromal interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation are dependent on extracellular matrix (ECM) proteins. Pancreas 28(1), 38-44 (2004)
K.Tsuchida, M. Nakatani, N. Yamakawa , O. Hashimoto, Y. Hasegawa, H. Sugino.
Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell. Endocrinol. 220 (1-2), 59-65 (2004)
K. Tsuchida, M. Nakatani, T. Matsuzaki, N. Yamakawa, Z.H. Liu, Y.L. Bao, K.Y. Arai, T. Murakami, Y. Takehara, A. Kurisaki & H. Sugino. Novel factors in regulation of activin signaling. Mol. Cell. Endocrinol. 225(1-2), 1-8 (2004)
K. Tsuchida. Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr. Drug Targets-Immune Endocr. Metabol. Disord. 4(2), 157-166 (2004)
|Speaker-11：||K. Tsuchida (2004)
Characterization of follistatin and FLRG as myostatin inhibiting proteins and novel therapeutic tools for treatment of muscular dystrophy.
International Symposium organized by Japanese Muscular Dystrophy
Research group. Molecular Therapy for Muscular Dystrophy, Part II
|Research History  (#12)|
|Papers-12：||K. Takamura, K. Tsuchida, H. Miyake, S. Tashiro, H. Sugino.
Possible endocrine control by follistatin 315 during liver regeneration based on changes of activin receptor after partial hepatectomy in rat.
Hepato-Gastroenterology 52(61), 60-66 (2005)
Y.L. Bao, K. Tsuchida, B. Liu, A. Kurisaki, T. Matsuzaki, H. Sugino.
Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through ERK1/ERK2 MAPK signaling pathways.
J. Endocrinology 184 (3), 493-504 (2005)
K. Takamura, K. Tsuchida, H. Miyake, S. Tashiro, H. Sugino.
Activin and activin receptor expression changes in liver regeneration in rat.
J. Surgical Research 126(1), 3-11 (2005)
|Speaker-12：||K. Tsuchida, M. Nakatani, S. Matsuo, H. Sugino. (2005) Generation of transgenic mouse models in which skeletal muscle mas is increased and adipocyte tissue mass and fat accumulation are decreased. The 10th Adiposcience Symposium Osaka, Japan, August 19-20.
K. Tsuchida. (2005) Regulation of myostatin activity by follistatin and related molecules. International Workshop for Therapeutic Strategies for Muscular Dystrophy by Myostatin Inhibition. Tokyo, Japan, October 29.
T. Murakami, J. Fan, H. Sawada, M. Yudasaka, S. Iijima, K. Tsuchida, K. Shiba. (2005) Water-dispersed carbon nanohorns and their potential application to drug carriers. 第4回ナノテクノロジー総合シンポジウム (JAPAN NANO 2006) Tokyo, Japan, February 20-21.
|Research History  (#13)|
|Papers-13：||K. Tsuchida. The role of myostatin and BMPs in muscular disorders. Expert Opin. Biol. Ther. 6, 147-154 (2006)
K.Y.Arai, K. Tsuchida, C.M. Li, G. Watanabe, H. Sugino, K. Taya, T. Nishiyama. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG). Protein Expr. Purif. 49(1), 78-82 (2006)
M. Funaba, T. Ikeda,M. Murakami, K. Ogawa, Y. Nishino, K. Tsuchida, H. Sugino, M. Abe. Transcriptional regulation of mouse mast cell protease-7 by TGF-β. Biochem. Biophys. Acta. 1759(3-4), 166-170 (2006)
Z.H. Liu, K. Tsuchida, T. Matsuzaki, Y.L. Bao, A. Kurisaki, H. Sugino.
Characterization of splicing variants of activin receptor-interacting protein 2 that augment activin signaling. J. Endocrinol. 189(2), 409-421 (2006)
M. Funaba, T. Ikeda,M. Murakami, K. Ogawa, Y. Nishino, K. Tsuchida, H. Sugino, M. Abe. Involvement of p38 MAP kinase and Smad3 in TGF-β-mediated mast cell functions. Cell. Signal. 18, 2154-2161 (2006)
M. Funaba, M. Murakami, T. Ikeda, K. Ogawa, K. Tsuchida, H. Sugino. Identification of tocophenol-associated protein as an activin/TGF-beta inducible gene in mast cells. Biochem. Biophys. Acta. 1763(8), 900-906 (2006)
M. Funaba, K. Nakaya, T. Ikeda, M. Murakami, K. Tsuchida, H. Sugino. Requirement of Smad3 for mast cell growth. Cell. Immunol. 240(1), 47-52 (2006)
M. Kogame, S. Matsuo, M. Nakatani, A. Kurisaki, H. Nishitani, K. Tsuchida, H. Sugino. ALK7 is a novel marker for adipocyte differentiation. J. Med. Invest. 53(3-4), 238-245 (2006)
K. Tsuchida,Y. Sunada, S. Noji, T. Murakami, A. Uezumi, M. Nakatani. Inhibitors for the TGF-β superfamily and their clinical applications. Mini. Rev. Med. Chem. 6(11), 1255-1261 (2006)
Y. Ohsawa, H. Hagiwara, M. Nakatani, A. Yasue, K. Moriyama, T. Murakami, K. Tsuchida, S. Noji, Y. Sunada. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J. Clin. Invest. 116(11), 2924-2934 (2006)
|Speaker-13：||K. Ajima, M. Yudasaka, A. Maigne, T. Murakami, K. Shiba, S. Iijima. (2006) Carbon Nanohors as Anticancer Drug Carriers. 11th International Ceramics Congress (CIMTEC 2006), Acireale, Sicily, Italy, June 5.
H. Sawada, R. Hishida, Y. Hirata, K. Ono, H. Suzuki, S. Muramatsu, I. Nakano, K. Tsuchida, T. Nagatsu, M. Sawada. (2006) Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 20 th IUBMB International Congress of Biochemistry and Molecular Biology and 11 th FAOBMB Congress, Kyoto, June 20.
M. Nakatani, H. Sawada, T. Murakami, K. Tsuchida. (2006) Adipose tissue mass and adipocyte size are reduced by transgenic expression of a follistatin-derived molecule to skeletal muscle due to myostatin inhibition. 20 th IUBMB International Congress of Biochemistry and Molecular Biology and 11 th FAOBMB Congress, Kyoto, June 21.
T. Murakami, J. Fan, H. Sawada, M. Yudasaka, S. Iijima, K. Tsuchida, K. Shiba. (2006) Water-dispersed carbon nanohorns as a potential drug carrier for cancer chemotherapy. 20 th IUBMB International Congress of Biochemistry and Molecular Biology and 11 th FAOBMB Congress, Kyoto, June 22.
A. Uezumi, S. Takeda, K. Tsuchida. (2006) Adipogenesis of CD31-CD45- side population cells in skeletal muscle. 11th Study Group on Adiposcience, Osaka, August 19.
K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, H. Sawada. (2006) Prevention of muscle atrophy and muscle degeneration in muscular dystrophy and ALS model mice by myostatin blockage. Neurons and Disease. The 4 th Neuron Satellite Meeting. Atlanta, USA, October 12-13
K. Ajima, M. Yudasaka, A. Maigne, T. Murakami, K. Shiba, S. Iijima. (2006) Single-wall carbon nanohorns as cisplatin carriers NANOBIO-TOKYO 2006, Hongo Campus, The University of Tokyo, December 6.
|Research History  (#14)|
|Papers-14：||K. Miyake, K. Tsuchida, H. Sugino, S. Imura, Y. Morine, M. Fujii, M. Shimada. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother. Pharmacol. 59(1), 113-126 (2007)
H. Sawada, H. Ishiguro, K. Nishii, K. Yamada, K.Tsuchida, H. Takahashi, J. Goto, I. Kanazawa, T. Nagatsu. Characterization of neuron-specific huntingtin aggregates in human huntingtin knock-in mice. Neurosci. Res. 57(4), 559-573 (2007)
Y. Morine, K. Tsuchida, H. Sugino, K. Takamura, S. Tashiro, M. Shimada. Effects of preactivation by portal vein ligation on liver regeneration following massive hepatectomy in rats. Hepatogastroenterology 54(76), 1216-1221 (2007)
K. Pryor-Koishi, H. Nishizawa, T. Kato, H. Kogo, T. Murakami, K. Tsuchida, H. Kurahashi, Y. Udagawa. Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. BJOG 114(9), 1128-1137 (2007)
Y. Takehara-Kasamatsu, K. Tsuchida, M. Nakatani, T. Murakami, A. Kurisaki, O. Hashimoto, H. Ohuchi, H. Kurose, K. Mori, S. Kagami, S. Noji, H. Sugino. Characterization of follistatin-related gene as a negative regulatory factor for activin family members during mouse heart development. J. Med. Invest. 54, 276-288 (2007)
Y. Shoji-Kasai, H. Ageta, Y. Hasegawa, K. Tsuchida, H. Sugino, K. Inokuchi. Activin, a member of the TGF-β superfamily, increases the number of synaptic contacts and the length of dendritic spine necks by modulating spinal actin dynamics. J. Cell Sci. 120, 3830-3837 (2007)
|Speaker-14：||K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami. Prevention of muscle atrophy and muscle degeneration in muscular dystrophy by myostatin blockage. Gordon Research Conference, Myogenesis. Il Ciocco, Italy, May13-18 (2007)
K. Tsuchida. Myostatin inhibition by follistatin-derived peptide ameliorates pathophysiology of muscular dystrophy model mice. 第７回日仏ワークショップ「筋ジストロフィーに対する治療を目指して」Shonan, Japan, June 8-9 (2007)
A. Uezumi, M. Nakatani, K. Tsuchida. Dynamic changes of skeletal muscle satellite cells and macrophages in myostatin-inhibited transgenic mice. FASEB Summer Research Conferences, Skeletal Muscle Satellite & Stem Cells, Indian Wells, CA, U.S.A. July 14-19 (2007)
M. Yudasaka, J. Miyawaki, T. Murakami, X. Jinaxun, K. Ajima, M. Zhang, F. Jing, K. Tsuchida, S. Iijima. DDS Application of Single-Wall Carbon Nanohorns第四回日韓シンポジウム Kyoto, October 28 (2007)
H. Ageta, A. Murayama, R. Migishima, S. Kida, K. Tsuchida, M. Yokoyama, K. Inokuchi. Activin is a key regulator for postnatal neurogenesis and anxiety level. Neuroscience2007, San Diego, U.S.A.November 3-7 (2007)
K. Tsuchida. Discovery and development of myostatin inhibitors to prevent muscle atrophy caused by neuromuscular disorders. 5 th Anniversary Congress of International Drug Discovery Science and Technology (IDDST), Xi!#%ap!#%an, China, December 6-11 (2007)
|Research History  (#15)|
|Papers-15：||M. Nakatani, Y. Takehara, H. Sugino, M. Matsumoto, O. Hashimoto, Y. Hasegawa, T. Murakami, A. Uezumi, S. Takeda, S. Noji, Y. Sunada, and K. Tsuchida. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J. 22(2), 477-487 (2008)
H. Ogino, S. Yano, S. Kakiuchi, H. Muguruma, K. Ikuta, M. Hanibuchi, H. Uehara, K. Tsuchida, H. Sugino and S. Sone. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in NK cell-depleted SCID mice. Clin. Cancer Res. 14(3), 660-667 (2008)
T. Murakami and K. Tsuchida. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini. Rev. Med. Chem. 8(2), 175-183 (2008)
A. Kurisaki, I. Inoue, K. Kurisaki, N. Yamakawa, K. Tsuchida, H. Sugino. Activin induces long-lasting N-methyl-d-aspartate receptor activation via scaffolding PDZ protein activin receptor interacting protein 1. Neuroscience 151(4), 1225-1235 (2008)
K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami and X. Cui. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine J. 55(1), 11-21 (2008)
H. Ageta, A. Murayama, R. Migishima, S. Kida, K. Tsuchida, M. Yokoyama, K. Inokuchi. Activin in the brain modulates anxiety-related behavior and adult neurogenesis. PLos ONE e1869 (2008)
K. Tsuchida. Targeting myostatin for therapies against muscle-wasting disorders. Curr. Opin. Drug Discov. Devel. (CODDD) 11(4), 487-494 (2008)
T. Murakami, H. Sawada, G. Tamura, M. Yudasaka, S. Iijima, and K. Tsuchida. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine 3(4), 453-63(2008)
M. Zhang, T. Murakami, K. Ajima, K. Tsuchida, A.S.D. Sandanayaka, O. Ito, S. Iijima, M. Yudasaka. Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy. Proc. Natl. Acad. Sci. U.S.A. 105(39), 14773-14778 (2008)
K. Tsuchida. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myologica 27(1), 14-18 (2008)
Y. Ohsawa, T. Okada, A. Kuga, S. Hayashi, T. Murakami, K. Tsuchida, S. Noji, Y. Sunada. Caveolin-3 regulates myostatin signaling. Mini-review. Acta Myologica 27(1), 19-24 (2008)
K. Ajima, T. Murakami, Y. Mizoguchi, K. Tsuchida, T. Ichihashi, S. Iijima, M. Yudasaka. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano 2(10), 2057-2064 (2008)
|Books-15：||K. Tsuchida. Drug delivery systems for cancer treatment. Encyclopedia of Cancer 2nd ed (Manfred Schweb Ed.) pp909-911 (2008)
K. Tsuchida, M. Nakatani, T. Murakami, A. Uezumi. Action of myostatin and its regulators in skeletal myogenesis. In Recent advances in skeletal muscle differentiation. (Editors K Tsuchida, S Takeda) Research Signpost. 109- 126 (2008)
|Speaker-15：||K. Tsuchida, M. Nakatani, A. Uezumi. T. Murakami. Transgenic expression of myostatin inhibitor derived from follistatin ameliorates muscular dystrophy model mice. 7th International Conference on BMPs. 7th International Conference on BMPs. California, U.S.A. July 9-13 (2008)
T. Murakami, H. Sawada, M. Yudasaka, S. Iijima, K. Tsuchida. Preparation and functional analyses of water-dispersed carbon nanohorns for cancer chemotherapy. Controlled Release Society 35th Annual Meeting & Exposition. New York, U.S.A. July 12-16 (2008)
A. Uezumi, S. Fukada, K. Tsuchida. Identification of mesenchymal progenitor cells responsible for fatty degeneration of skeletal muscle. EMBO Myogenesis Conference, Barcerona, Spain. September 24-29 (2008)
K. Tsuchida, M. Nakatani, A. Uezumi. Myostatin inhibiting peptide works as a magic bullet to increase skeletal muscle mass and to ameliorate muscle pathology in muscular diseases by transgenic expression. 2nd World Conference on Magic Bullets (Ehrlich II) Nurenberg, Germany. October 3-5 (2008)
|Research History  (#16)|
|Papers-16：||M. Sekiguchi, F. Hayashi, K. Tsuchida, K. Inokuchi. Neuron type-selective effects of activin on development of the hippocampus. Neuroscience Letters 452(3), 232-237 (2009)
A. S. D. Sandanayaka, O. Ito, M. Zhang, K. Ajima, S. Iijima, M. Yudasaka, T. Murakami, K. Tsuchida. Photoinduced electron transfer in Zinc phthalocyanine loaded on single-walled carbon nanohorns in aqueous solution. Advanced Materials 21(43), 4366-4371 (2009)
J. Miyawaki, S. Matsumura, R. Yuge, T. Murakami, S. Sato, A. Tomida, T. Tsuruo, T. Ichihashi, T. Fujinami, H. Irie, K. Tsuchida, S. Iijima, K. Shiba, M. Yudasaka. Biodistribution and ultrastructural localization of single-walled carbon nanohorns determined in vivo with embedded Gd2O3 labels. ACS nano 3(6), 1399-1406 (2009)
K. Tsuchida, M. Nakatani, K. Hitachi, A. Uezumi, Y. Sunada, H. Ageta, K. Inokuchi. Activin signaling as an emerging target for therapeutic intervention. Cell Commun. Signal 7(1), 15 (2009)
H. Gilson, O. Schakman, S. Kalista, P. Lause, K. Tsuchida, J. Thissen. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am. J. Physiol. Endocrinol & Metabol. 297(1), 157-164 (2009)
Y. Oshima, N. Ouchi, M. Shimano, D.R. Pimentel, K.N. Papanicolaou, K.D. Panse, K. Tsuchida, E. Lara-Pezzi, S.-J. Lee, K. Walsh. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 120(16), 1606-1615 (2009)
K. Jinno, T. Takahashi, K. Tsuchida, E. Tanaka, K. Moriyama. Acceleration of palatal wound healing in Smad3-deficient mice. J. Dental Res. 88(8), 757-761 (2009)
|Books-16：||A. Uezumi, K. Tsuchida. Roles of mesenchymal progenitors, distinct from satellite cells, in muscle pathology and physiology. In Muscle Cell Physiology (Edited by Y. Ohira) Osaka University Press pp109-119 (2009)|
|Speaker-16：||H. Gilson, O. Schakman, S. Kalista, P. Lause, K. Tsuchida, J.P. Thissen. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. 91 th Annual Meeting of Endocrine Society. June 10-13 (2009)
A. Uezumi, S. Fukada, H. Yamada, S. Takeda, K. Tsuchida. Mesenchymal progenitors distinct from muscle satellite cells contribute to ectopic fat formation in skeletal muscle. Making Muscle in the Embryo and the Adult. New York, U.S.A. May 28-June 2 (2009)
J. Miyawaki, S. Matsumura, R. Yuge, T. Murakami, S. Sato, A. Tomida, T. Tsuruo, T. Ichihashi, T. Fujinami, H. Irie, K. Tsuchida, S. Iijima, K. Shiba, M. Yudasaka. Biodistribution and ultrastructural localization of single-walled carbon nanohorns determined in vivo with embedded Gd2O3labels. 2nd Carbon Nanotube Biology, Medicine & Toxicology. Beijin, June 20 (2009)
T. Murakami, W. Wijagkanalan, M. Hashida, K. Tsuchida. Intracellular drug delivery by cell-penetrating high density lipoprotein. 10th US-Japan Symposium on Drug Delivery Systems. Hawaii, U.S.A. December 16-20 (2009)
K. Tsuchida. Preparation and functional characterization of drug-loaded carbon nanomaterials for cancer chemotherapy. BIT’s 3rd World Congress of Gene-2009 Foshan, China, December 5 (2009)
|Research History  (#17)|
|Papers-17：||A. Uezumi, S. Fukada, N. Yamamoto, S.I. Takeda, K. Tsuchida. Mesenchymal progenitors distinct from muscle satellite cells contribute to ectopic fat formation in skeletal muscle. Nature Cell Biology 12(2), 143-152 (2010)
H. Ageta, S. Ikegami1 M. Miura, M. Masuda, R. Migishima, T. Hino, N. Takashima, A. Murayama, H. Sugino, M. Setou, S. Kida, M. Yokoyama, Y. Hasegawa, K. Tsuchida, T. Aosaki, K. Inokuchi. Activin plays a key role in the maintenance of long-term memory and late-LTP. Learning and memory 17(4), 176-185 (2010)
T. Murakami, K. Tsuchida, M. Hashida, H. Imahori. Size control of lipid-based drug carrier by drug loading. Mol. BioSystems 6, 789-791 (2010)
T. Murakami, W. Wijagkanalan, M. Hashida, K. Tsuchida. Intracellular drug delivery by genetically engineered high density lipoprotein nanoparticle. Nanomedicine 5(6), 867-879 (2010)
S.-J. Lee, Y.-S. Lee, T. A. Zimmers, A. Soleimani, M. M. Matzuk, K. Tsuchida, R. D. Cohn, E. R. Barton. Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24(10), 1998-2008 (2010)
M. Ishikawa, N. Nishijima, J. Shiota, H. Sakagami, K. Tsuchida, M. Mizukoshi, M. Fukuchi, M. Tsuda, A. Tabuchi. Involvement of the SRF coactivator megakaryoblastic leukemia in the activin-regulated dendritic complexity of rat cortical neurons. J. Biol. Chem. 285(43), 32734-32743 (2010)
|Books-17：||H. Ageta, K. Tsuchida. Multifunctional roles of activins in the brain. Vitamins and Hormones Vol. 85: Activin and Inhibin (2010)(Invited review)(in press)|
|Speaker-17：||K. Tsuchida.(2010) 3 rd Pan Pacific Symposium on Stem Cells Research. Taiwan, April 16~20.|
Wed Dec 22 18:28:53 JST 2010